THALES
Thales announces a new data protection capability for Microsoft customers to benefit from the power of the full range of Microsoft 365 applications while protecting sensitive data in the cloud and meeting major data privacy regulations and requirements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210316005009/en/
Designed for companies that operate in highly-regulated sectors such as financial services and healthcare, they can now leverage Thales Luna Hardware Security Modules (HSMs) with Double Key Encryption for Microsoft 365 and comply with regulations such as the EU General Data Protection Regulation (GDPR), the Health Insurance Portability and Accountability Act (HIPAA), and the recommendations from the European Data Protection Board (EDPR) following the Schrems II ruling.
Securing Data in the Era of Remote Working and Increased Privacy Regulations
Today’s remote working environment relies heavily on the collaborative sharing of information, challenging organisations to maintain the security of confidential data and regulatory compliance while driving employee productivity. For organisations in highly regulated industries such as financial services, governments, and healthcare, their sensitive data requires the highest level of control and security. The integration of Luna HSMs with Double Key Encryption for Microsoft 365 delivers the protection required to protect highly sensitive data and meet unique regulatory requirements.
“The premise of remote working is no longer a perk reserved for a select few, but now the default operating model for many companies,” said Imran Mohiuddin, DKE partner director at Microsoft. “Our collaboration and productivity tools for Microsoft 365 customers are designed to enable companies to thrive in any situation. A key part in enabling this to happen though is ensuring they have the best security and compliance solutions when it comes to protecting sensitive data. Our Double Key Encryption integration with Thales enables customers who have enhanced data protection requirements, compliance obligations and regulatory restrictions to protect their highly sensitive information. By having full control of their encryption keys, customers can be certain that no third-party has access to their unencrypted data -- including Microsoft. Security should never be something that holds companies back in this remote era and from moving their sensitive information to the cloud, and with Thales, we’re ensuring it won’t for our customers.”
Thales has integrated its industry-leading Luna HSMs with Microsoft Double Key Encryption for Microsoft 365. This allows customers to protect their most confidential or sensitive data while maintaining control of their encryption keys in the cloud. The solution works by using two keys to protect data. One key is managed securely by the customer via the Luna HSM and a second key in Microsoft’s control. To view the data, one must have access to both keys, meaning it can’t be used without the customer’s permission.
“Our collaboration with Microsoft is designed to give peace of mind to customers when it comes to security, no matter where or what Microsoft applications they’re accessing,” said Todd Moore, vice president of encryption solutions at Thales. “The way we work has changed forever and in order to thrive, businesses have had to increasingly adapt and adopt collaborative applications. The integration of Thales Luna HSMs with Microsoft Double Key Encryption provides businesses with control over their encrypted data, in line with regulatory requirements, regardless of their industry.”
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions. Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
|
PLEASE VISIT
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005009/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vonage Network APIs Pave the Way for Freenow by Lyft to Advance Urban Mobility Innovation22.1.2026 08:00:00 CET | Press release
Freenow adopts Vonage APIs to access network capabilities, strengthening fraud prevention through faster, verified connections with drivers for millions of riders Vonage, a part of Ericsson, and Freenow by Lyft, a leading taxi and multi-mobility app in Europe, have expanded their partnership with the launch of Vonage Silent Authentication API for customers based in the U.S. Vonage Network APIs enable Freenow by Lyft to tap into real-time network data and insights, helping prevent fraud through seamless user verification, ensuring reliable, efficient, and secure interactions for its customers and drivers. Network intelligence is becoming a critical layer of defense in the transportation space as fraud threats become more sophisticated and targeted. Enterprises worldwide lost 7.7% of their annual revenue on average due to fraud over the past year, representing an estimated $534 billion in losses.¹ With scam/authorization fraud, synthetic identity fraud, and account takeover as the leadin
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe22.1.2026 07:30:00 CET | Press release
Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe. Dr. Jürgen Müller will retire after nearly 30 years of research work at Daiichi Sankyo. Under his leadership, the Translational Research Center Europe, previously called the Tissue and Cell Research Center Munich, has grown from three to 40 researchers since it was founded in 1997 and has become an internationally recognized institution that plays a strategic role in the global innovation process of Daiichi Sankyo. Dr. Veronika Rozehnal joined Daiichi Sankyo in 2009 and has held various positions at the Translational Research Center Europe in addition to spending three years at the Daiichi Sankyo R&D Center in Tokyo. Dr. Rozehnal graduated from Ernst-Moritz-Arndt University of Greifswald, Germany with a Ph.D. degree in Clinical Pharmacology. “Jürgen Müller has made significant scientific contributions that have helped Daiichi Sankyo
Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 202622.1.2026 07:00:00 CET | Press release
Five presentations will showcase nizubaglustat’s therapeutic potential in Lysosomal Storage Disorders. Nizubaglustat is currently being tested in two global Phase 3 studies for Niemann-Pick type C disease and GM1/GM2 gangliosidoses which are currently recruiting. Azafaros will host a satellite symposium on nizubaglustat on Day 2 of the symposium discussing the Phase 3 studies. WORLDSymposium™ 2026 takes place from February 2 to 6 in San Diego, California. Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will feature in five scientific presentations accepted at the WORLDSymposium™ 2026, the leading global conference on lysosomal diseases, taking place in San Diego, California, USA between February 2-6. The company’s conference activities include: Oral Presentations (including Poster numbers 134 and 29-C) Long-term data from a Phase II study wit
I Squared Announces Launch of Radiant Energy Solutions22.1.2026 07:00:00 CET | Press release
I Squared Capital (“I Squared”), a leading global infrastructure investment manager, announced today the launch of Radiant Energy Solutions (“Radiant”), an investment from I Squared’s Middle East infrastructure strategy, which is focused on targeting transformational, mid-market investments in the region. Reflecting I Squared’s platform-building approach of starting with a core initial investment and scaling over time to build market-leading businesses, Radiant marks the firm’s entry into the Middle East distributed renewables market, providing decarbonization solutions to commercial and industrial customers. The investment for Radiant is the acquisition of FAS Renewables and its 100% owned subsidiary Zahra Energy, a Saudi Arabia–based distributed solar company with a secured and advanced portfolio of over 100MWp of distributed solar projects with established customers and long-term contracted solar power purchase agreements. These include Cenomi Centers, an owner, operator, and develo
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio22.1.2026 07:00:00 CET | Press release
At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7 Multiple studies will reinforce the safety and efficacy of Galderma’s hyaluronic acid (HA) treatments range, including post-marketing data on Restylane® Shaype™ in shaping the chin, Restylane Lyft™ in improving jawline definition, Restylane Skinboosters™ in smoothing fine lines and wrinkles in the décolletage and Restylane Volyme™ in correcting hollowing of the temples8-11 New data on the innovative neuromodulator Relfydess™ (RelabotulinumtoxinA) will reinforce its rapid onset as early as Day 1 and sustained efficacy through six months for frown lines and crow’s feet12 As a leader in injectable aesthetic innovation, Galderma will showcase its superior science and edu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
